Felix Mario, Farrukh Larabe, Modi Simple, Peredo-Wende Ruben
Department of Rheumatology, Yale School of Medicine, New Haven, USA.
Internal Medicine, Albany Medical Center, Albany, USA.
Cureus. 2022 Nov 30;14(11):e32078. doi: 10.7759/cureus.32078. eCollection 2022 Nov.
Multisystem inflammatory syndrome (MIS) is a severe inflammatory response that occurs days to weeks following the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). Initially known in children and named MIS-C, recently several cases of MIS in adults have been reported to the Centers for Disease Control and Prevention (CDC), leading to the recognition of a new disease MIS in adults (MIS-A). The current treatment options include high-dose steroids, intravenous immunoglobulin (IVIG), and immunosuppressive therapy. However, the pharmacologic approach remains limited to case reports and pending official guidelines to treat cases with MIS-A. We present a case of an adult patient who had a severe inflammatory state following COVID-19 infection, who was treated with IL-1 antagonist therapy with a successful outcome.
多系统炎症综合征（MIS）是一种严重的炎症反应，发生在严重急性呼吸综合征冠状病毒2（SARS-CoV-2，即导致2019冠状病毒病（COVID-19）的病毒）感染后的数天至数周。最初在儿童中被发现并命名为MIS-C，最近美国疾病控制与预防中心（CDC）报告了几例成人MIS病例，从而使成人新型疾病MIS（MIS-A）得到确认。目前的治疗选择包括大剂量类固醇、静脉注射免疫球蛋白（IVIG）和免疫抑制疗法。然而，药物治疗方法仍仅限于病例报告，且有待官方指南来治疗MIS-A病例。我们报告一例成年患者，其在COVID-19感染后出现严重炎症状态，接受白细胞介素-1拮抗剂治疗并取得成功。
